Published in TB and Outbreaks Week, July 31st, 2007
ACAM-FLU-A is designed to be a universal vaccine candidate targeting all 'A' strains of the influenza virus. As such, it has the potential to be both a universal pandemic influenza vaccine and part of a universal seasonal vaccine. Historically, influenza pandemics have been caused by 'A' strains of the virus while seasonal vaccines target both 'A' and 'B' strains of the virus.
The Phase 1 trial is:
A randomised, double-blind, placebo-controlled,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week